Biotechnology

Company Overview of Mirna Therapeutics, Inc.

Company Overview

Mirna Therapeutics, Inc. operates as a biopharmaceutical company that develops microRNA-based oncology therapeutics. It offers MRX34 to deliver a mimic of the naturally occurring microRNA tumor suppressor, miR-34, which is lost or under expressed in tumors of patients with various cancers, including cervical cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma (liver cancer), colon cancer, non-small cell lung cancer, and in cancer stem cells. The company was founded in 2007 and is based in Austin, Texas. Mirna Therapeutics, Inc. operates as a subsidiary of Asuragen, Inc.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.